Clinical trials located in

Manises

Manises city is located in Spain. Currently, 10 clinical trials are being conducted in this city.

Manises, located in the province of Valencia, Spain, is renowned for its rich ceramics tradition dating back to the 14th century. This city, nestled on the banks of the Turia River, has become synonymous with high-quality pottery and tile production, influencing both Spanish and international ceramic art. Manises also hosts an annual International Ceramics Festival, celebrating its deep-rooted heritage. Additionally, it is home to Valencia Airport, serving as a key gateway to the region. The city’s historical significance is further highlighted by its well-preserved medieval architecture.

  • CT-EU-00054021

    Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    • Brodalumab
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    • Ruxolitinib
  • Testing new treatments for hidradenitis suppurativa

    A thorough study is being conducted to evaluate the safety and effectiveness of various investigational treatments for individuals with moderate to severe Hidradenitis Suppurativa (HS), a long-term skin condition characterized by small, painful lumps under the skin. The treatments being tested include CFZ533, LYS006, MAS825, LOU064, and VAY736. Participants in the study will receive one of these potential treatments, aiming to discover whether these novel therapies can significantly reduce the severity of symptoms, improve skin appearance, and enhance the overall quality of life for those affected by this challenging and often painful condition. Throughout the study, participants will undergo regular health checks, including skin assessments and evaluations of any side effects, to ensure their safety and the effectiveness of the treatments.

    • iscalimab/CFZ533
    • LYS006- new potential medication for hidradenitis suppurativa
    • MAS825- new potential medication for inflammatory diseases
    • Remibrutinib/LOU064
    • Ianalumab/VAY736
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluating the impact of upadacitinib on Hidradenitis Suppurativa

    The aim of this study is to evaluate the effects of a drug called upadacitinib on people suffering from a skin condition called Hidradenitis Suppurativa (HS). HS causes painful sores, mainly in areas such as the armpits, groin, and anal and genital areas. The drug has already been approved to treat other conditions, such as ulcerative colitis and rheumatoid arthritis, but now doctors want to see if it can help HS patients who don’t respond to current treatments. The study was divided into three parts. First, participants will be randomly assigned to two different groups, one group will take upadacitinib and the other will take a placebo (a substance with no active effect). Neither participants nor doctors will know what treatment a person is receiving. The study lasts a year and a half, and patients take pills every day. Depending on the results obtained, they may proceed to further stages of the study. Participants’ health will be closely monitored through regular check-ups, surveys, and monitoring for any side effects.

    • Upadacitinib
  • Studying povorcitinib safety and effects on nonsegmental vitiligo

    This trial studies the effectiveness and safety of povorcitinib for nonsegmental vitiligo. Participants will receive Povorcitinib or a placebo for 52 weeks. The study aims to see if Povorcitinib can significantly improve vitiligo symptoms on the face and body. It’s open to adults with a clinical diagnosis of nonsegmental vitiligo. Safety, side effects, and treatment efficacy are key focuses, aiming to advance vitiligo treatments and care.

    • povorcitinib
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Safety and efficacy study of lebrikizumab for atopic dermatitis in children and adolescents

    A clinical trial to test the safety and efficacy of a drug called lebrikizumab in children and adolescents suffering from moderate to severe atopic dermatitis, commonly known as eczema. The study involves participants between the ages of 6 months and 18 years to monitor how well their bodies absorb the drug. Participants receive a saturating dose of the drug, followed by subsequent doses. The number of doses depends on the participant’s weight. The study also includes a control group that will receive a placebo. The effect of the treatment will be measured by various tests, such as the severity index, itch score and quality of life index.

    • Lebrikizumab

See more clinical trials in other cities in Spain:

.